Impact of a Moderate-Fat Meal on the Bioavailability of Ribavirin in Patients with Hepatitis C

Authors

  • Ibrahim Altraif Division of Hepatology - Hepatobiliary Sciences & Organ Transplant Center - MNGHA, King Abdullah International Medical Research Center/King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia Author
  • Sara Altraif Family Medicine Department, King Khalid University Hospital. Riyadh, Saudi Arabia Author
  • Shazia Murtaza King Abdullah International Medical Research Center/King Saud bin Abdulaziz University for Health Sciences, Research Office – MNGHA, Riyadh, Kingdom of Saudi Arabia Author
  • Abdulkareem Albekairy Department of Pharmaceutical Care – MNGHA, King Abdullah International Medical Research Center/King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia Author
  • Naila Shaheen Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia Author
  • Mohammed Hussein Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia Author
  • Altaf Khan Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia Author

Keywords:

Hepatitis C virus, Genotype 4, Ribavirin, Bioavailability, Saudi Arabia

Abstract

Graphical abstract

Impact of a Moderate-Fat Meal on the Bioavailability of Ribavirin in Patients with Hepatitis C

References

https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c

Altraif, I., Handoo, F. (2004) Chronic Hepatitis C Genotype and Response to Antiviral therapy among Saudi Patients. Saudi Medical Journal, 25(12): 1935-1938.

http://www.easl.eu/medias/cpg/HCV2016/Summary.pdf

Tam, RC., Lau, JY., Hong, Z. (2002) Mechanisms of action of ribavirin in antiviral therapies. Antiviral Chem Chemother, 12(5): 261-272.

Seeff, LB., Hoofnagle, JH. (2002) National Institutes of Health Consensus Development Conference statement: Management of hepatitis C. Hepatology, 36(5): S3-20.

Brunton, LL., Lazo, JS., Parker, KL. (2006) The Pharmacological Basis of Therapeutics. 11thedn, Goodman and Gilman’s, New York.

https://reference.medscape.com/drug/rebetol-ribasphereribavirin-342625 (accessed 24 June 2019).

Glue, P. (1999) The clinical pharmacology of ribavirin. Semin in Liver Dis, 19(1): 17-24.

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__ Scientific_Discussion/human/000246/WC500048207.pdf

Wade, JR., Snoeck, E., Duff, F., Lamb, M., Jorga, K. (2006) Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol, 62(6): 710–714.

Graphical abstract

Downloads

Published

2019-08-21

Issue

Vol. 2 No. 2 (2019)

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Impact of a Moderate-Fat Meal on the Bioavailability of Ribavirin in Patients with Hepatitis C. (2019). Annals of Gastroenterology and Digestive Disorders, 2(2). https://somatopub.com/index.php/AGDD/article/view/187